All Oncology News

A retrospective analysis of 3234 patients with CLL/SLL showed that over half of those 75 to 79 years of age went on to receive second-line therapy.

Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.

External validation of a circulating immune protein signature model confirmed its prognostic value for OS in recurrent ovarian cancer.

To figure out how to beat persister tumor cells, researchers at UCSF built a robotic system that treats thousands of mini tumors at once in the laboratory.

Experts in lung cancer gathered at an OncLive® Scientific Interchange and Workshop during the 2026 ASCO Annual Meeting to discuss HER2-mutated NSCLC.

Iza-bren improved PFS, OS, and response rates vs chemotherapy in pretreated metastatic TNBC, indicating a potential new standard of care.

Everett Meyer, MD, PhD, outlines ongoing research and the potential role for Orca-T in advanced hematologic malignancies.

A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.

Pumitamig plus chemotherapy generated strong responses across NSCLC subtypes and PD-L1 levels with manageable safety in ROSETTA Lung-02.

Premal Thaker, MD, MS, discusses the role for CDK2 inhibition in platinum-resistant ovarian cancer.

Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses data from subgroup analyses of the PSMAddition trial by disease volume and in de novo/recurrent mHSPC.

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.

Emi-Le generated durable responses and encouraging PFS with manageable safety in patients with aggressive adenoid cystic carcinoma.

Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.

Zanubrutinib yielded sustained progression-free survival and a tolerable safety profile in older patients with CLL/SLL treated in the SEQUOIA trial.

Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.

Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.

Rocbrutinib delivered durable responses and encouraging survival with manageable safety in BTK inhibitor–pretreated relapsed/refractory MCL.

Dana-Farber investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial in smoldering myeloma.

Vincent Picozzi, MD, discusses the PANOVA-3 data supporting the approval of Optune Pax and the future of TTFields in pancreatic cancer.

The FDA has accepted a BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.

Learn how ESR1 mutations drive endocrine resistance and how FDA-approved oral SERDs improve outcomes, shaping smarter sequencing and future combos.

Cadonilimab plus axitinib demonstrated an ORR of 51.6% and manageable safety in frontline advanced nccRCC.

ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.

Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML.

The first-in-class BTK degrader tacabrutideg produced an ORR of 94.1% at the recommended phase 2 dose in relapsed/refractory CLL/SLL.

Gilteritinib generated comparable OS outcomes vs midostaurin in newly diagnosed FLT3-mutated AML, failing to meet the phase 3 trial primary end point.

Ziftomenib plus 7+3 yielded high CR and MRD-negativity rates with manageable safety in newly diagnosed NPM1/KMT2A-mutated AML.